Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to
evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent
reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.